Xolair (Omalizumab): New Hope for People with Food Allergies
Learn how Xolair (omalizumab) reduces allergic reactions by targeting IgE. Clinical trials show increased tolerance to peanuts, milk, egg and more.
Xolair (Omalizumab): New Hope for People with Food Allergies
Food allergies can change daily life—affecting meals, social events, and peace of mind. Xolair (generic name: omalizumab ) is a monoclonal antibody that targets IgE , the antibody central to many allergic reactions. Recent high-quality clinical research shows that Xolair can raise the threshold for reaction to multiple foods, offering meaningful protection against accidental exposures for some patients. What is Xolair (omalizumab)? Xolair is an FDA-approved monoclonal antibody originally used for allergic asthma, chronic spontaneous urticaria, and nasal polyps. In 2024–2025, clinical trial data supported its use to reduce allergic reactions from accidental exposure to one or more IgE-mediated food allergens in children and adults (age 1 and up). Xolair is administered by injection at regular intervals under medical supervision. How Xolair Works Xolair binds to free IgE antibodies in the bloodstream, preventing IgE from attaching to receptors on mast cells and basophils. This reduces the abi…
